cheerleader wrote:Sorry, Cece. What a drag. Jeff can relate. He got the lecture to start Tysabri from his neuro last spring (even though he has no new symptoms, no inflammation, no new lesions, reduction of gray matter atrophy and huge symptom relief.) She told him he was "lucky so far"--no thanks to venoplasty three years earlier, or lifestyle and diet changes. He was a man, and was going to progress and want a stronger drug. Unbelievable. So much negativity....not good. But that's what they are told to do at every single pharma conference/meeting/salespitch they attend. Hang in there--and enjoy your life.
I consider Tysabri a drug of last resort, considering the side effects, and for him to be asked to consider it when he's doing as well as he is? Makes no sense.
My neuro is doing a research study on BG12
An Open-Label, Multicenter Study in Subjects with Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
Purpose of study
To evaluate the safety and determine if the investigational drug BG0012, when taken in combination with another prescribed MS therapy, improves MS symptoms. You may be eligible for this study if you have relapsing-remitting MS, have been on an MS therapy for at least one year and still have symptoms.
Jonathan Calkwood, M.D.
Clinical Trial Sponsor
Clinical trial sponsor Biogen
and here he is giving a presentation on BG-12
https://conferencecenter.msworld.org/cm ... le-with-ms
I think he genuinely believes it's a useful drug, but I think I'm with NHE on the idea of using other Nrf2 activators such as curcumin. What were those main ingredients of protandim again? Curcumin, green tea extract, and milk thistle. There was an abstract showing prontandim to be more effective than BG-12, I will have to find it, and bring it with to my next appt.
Sometimes pharmaceutical companies sponsor trials just to get the doctors comfortable with the drug. It's marketing, and it works.